SCHEMBL132215

SCHEMBL132215

[CH2]Cc1cccc([N+](=O)[O-])c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.67
LMNA P02545 2/20 0.61
CYP1A2 P05177 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
ALDH1A1 P00352 5/20 0.52
ACHE P22303 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
ALOX15 P16050 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.51
KMT2A Q03164 3/20 0.50
POLB P06746 2/20 0.50
MEN1 O00255 2/20 0.50
MAPT P10636 2/20 0.50
HSP90AA1 P07900 1/20 0.50
PYCR1 P32322 1/20 0.50
HTT P42858 2/20 0.49
DDX3X O00571 1/20 0.49
CTDSP1 Q9GZU7 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7207567 0.85 TSHR (0.62) TSHRLMNACYP1A2CYP2D6CYP2C9
SCHEMBL2497572 0.84 TSHR (0.67) TSHRLMNACYP1A2CYP2D6CYP2C9
SCHEMBL10918542 0.83 TSHR (0.71) TSHRLMNACYP1A2CYP2D6CYP2C9
SCHEMBL7328646 0.82 TSHR (0.59) TSHRLMNACYP1A2CYP2D6CYP2C9
SCHEMBL94845 0.82 TSHR (0.69) TSHRLMNACYP1A2CYP2D6CYP2C9
SCHEMBL8713184 0.82 TSHR (0.69) TSHRLMNACYP1A2CYP2D6CYP2C9
SCHEMBL3147589 0.80 TSHR (0.57) TSHRLMNACYP1A2CYP2D6CYP2C9
SCHEMBL3029808 0.80 TSHR (0.57) TSHRLMNACYP1A2CYP2D6CYP2C9
SCHEMBL8245788 0.80 TSHR (0.67) TSHRLMNACYP1A2CYP2D6CYP2C9
SCHEMBL189560 0.80 TSHR (0.67) TSHRLMNACYP1A2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10065926-B2 Use of substituted dihydrooxindolylsulfonamides, or the salts thereof, for increasing the stress tolerance of plants BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2018-09-04 US claimed
EP-3051946-B1 USE OF SUBSTITUTED DIHYDROOXINDOLYLSULFONAMIDES OR THEIR SALTS FOR INCREASING STRESS TOLERANCE IN PLANTS BAYER CROPSCIENCE AG (DE) 2017-11-29 EP claimed
US-20160237035-A1 USE OF SUBSTITUTED DIHYDROOXINDOLYLSULFONAMIDES, OR THE SALTS THEREOF, FOR INCREASING THE STRESS TOLERANCE OF PLANTS BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2016-08-18 US claimed
EP-3051946-A1 USE OF SUBSTITUTED DIHYDRO-OXINDOLYL SULFONAMIDES, OR THE SALTS THEREOF, FOR INCREASING THE STRESS TOLERANCE OF PLANTS Bayer CropScience Aktiengesellschaft (DE) 2016-08-10 EP claimed
WO-2015049351-A1 USE OF SUBSTITUTED DIHYDRO-OXINDOLYL SULFONAMIDES, OR THE SALTS THEREOF, FOR INCREASING THE STRESS TOLERANCE OF PLANTS BAYER CROPSCIENCE AG (DE) 2015-04-09 WO claimed
EP-0031104-A1 Thiazolidine compounds, processes for their preparation and pharmaceutical compositions containing them SANTEN PHARMACEUTICAL CO., LTD. (JP) 1981-07-01 EP claimed
CN-116217471-A Pterocarpus stilbene pyridine salt compound, intermediate compound, composition, medicine, preparation method and application 贵州大学 2023-06-06 CN disclosed
WO-2023076453-A1 TREATING NEUROINFLAMMATORY CONDITIONS AN2 THERAPEUTICS, INC. (US) 2023-05-04 WO disclosed
US-20230018615-A1 STEROIDS AND METHODS OF MANUFACTURE TRUSTEES OF DARTMOUTH COLLEGE 2023-01-19 US disclosed
EP-3153023-B1 BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE TAKEDA PHARMACEUTICALS CO (JP) 2022-03-16 EP disclosed
US-20210253566-A1 CYTOCHROME P450 INHIBITORS AND USES THEREOF ANGION BIOMEDICA CORP. 2021-08-19 US disclosed
CN-112961149-A Cytochrome P450 inhibitors and uses thereof 安吉恩生物医药公司 2021-06-15 CN disclosed
US-20210171515-A1 CYTOCHROME P450 INHIBITORS AND USES THEREOF ANGION BIOMEDICA CORP. 2021-06-10 US disclosed
US-4256746-A ANTITUMOR AGENTS; MICROBIOCIDES; MITOSIS TAKEDA CHEMICAL INDUSTRIES (JP) 1981-03-17 US disclosed
EP-0014402-A1 Novel 20-0-acylmaytansinoids, process for their preparation and pharmaceutical compositions containing them Takeda Chemical Industries, Ltd. (JP) 1980-08-20 EP disclosed
EP-0011277-A1 Dechloromaytansinoids, their production and use and pharmaceutical compositions containing them Takeda Chemical Industries, Ltd. (JP) 1980-05-28 EP disclosed
EP-0011276-A1 Maytansinoids, their production and use Takeda Chemical Industries, Ltd. (JP) 1980-05-28 EP disclosed
US-4125622-A ANTITHROMBOSIS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1978-11-14 US disclosed
US-4123607-A BACTERICIDES AMERICAN CYANAMID COMPANY (US) 1978-10-31 US disclosed
US-4048431-A BACTERICIDES AMERICAN CYANAMID COMPANY (US) 1977-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171515-A1 CYTOCHROME P450 INHIBITORS AND USES THEREOF CYP7A1, CYP2E1, CYP11B1 TSHR 3893/4885LMNA 2070/4885CYP1A2 4/4885
US-10065926-B2 Use of substituted dihydrooxindolylsulfonamides, or the salts thereof, for increasing the stress tolerance of plants SQOR, DHPS, QDPR TSHR 4125/4885LMNA 4818/4885CYP1A2 606/4885
US-20230018615-A1 STEROIDS AND METHODS OF MANUFACTURE HSD17B7, HSD11B1, HSD11B2 TSHR 265/4885LMNA 1098/4885CYP1A2 133/4885
US-20210253566-A1 CYTOCHROME P450 INHIBITORS AND USES THEREOF CYP7A1, CYP2E1, CYP1A2 TSHR 3998/4885LMNA 2143/4885CYP1A2 3/4885
US-20160237035-A1 USE OF SUBSTITUTED DIHYDROOXINDOLYLSULFONAMIDES, OR THE SALTS THEREOF, FOR INCREASING THE STRESS TOLERANCE OF PLANTS SQOR, DHPS, QDPR TSHR 4125/4885LMNA 4818/4885CYP1A2 606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.